Recursion Pharmaceuticals Financials
| RXRX Stock | USD 5.89 0.11 1.83% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.47 | 4.7025 |
|
|
The essential information of the day-to-day investment outlook for Recursion Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Recursion Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Recursion Pharmaceuticals.
Net Income |
|
Recursion | Select Account or Indicator |
Understanding current and past Recursion Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Recursion Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Recursion Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Recursion Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Recursion Pharmaceuticals. Check Recursion Pharmaceuticals' Beneish M Score to see the likelihood of Recursion Pharmaceuticals' management manipulating its earnings.
Recursion Pharmaceuticals Stock Summary
Recursion Pharmaceuticals competes with Bright Minds, HP, Intel, Chevron Corp, and Coca Cola. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Recursion Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 400 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US75629V1044 |
| CUSIP | 75629V104 |
| Location | Utah; U.S.A |
| Business Address | 41 South Rio |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.recursion.com |
| Phone | 385 269 0203 |
| Currency | USD - US Dollar |
Recursion Pharmaceuticals Key Financial Ratios
| Return On Equity | -0.78 | ||||
| Operating Margin | (3.77) % | ||||
| Price To Sales | 35.13 X | ||||
| Revenue | 44.58 M | ||||
| Gross Profit | (164.13 M) |
Recursion Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Recursion Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Recursion Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Recursion Pharmaceuticals competition to find correlations between indicators driving Recursion Pharmaceuticals's intrinsic value. More Info.Recursion Pharmaceuticals is currently regarded as top stock in return on equity category among its peers. It is rated third in return on asset category among its peers . At this time, Recursion Pharmaceuticals' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Recursion Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Recursion Pharmaceuticals Systematic Risk
Recursion Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Recursion Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was four with a total number of output elements of fifty-seven. The Beta measures systematic risk based on how returns on Recursion Pharmaceuticals correlated with the market. If Beta is less than 0 Recursion Pharmaceuticals generally moves in the opposite direction as compared to the market. If Recursion Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Recursion Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Recursion Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Recursion Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Recursion Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Recursion Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Recursion Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Recursion Pharmaceuticals November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Recursion Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Recursion Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Recursion Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Recursion Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Recursion Pharmaceuticals's daily price indicators and compare them against related drivers.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 20.99 | |||
| Value At Risk | (6.37) | |||
| Potential Upside | 5.95 |
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.